Associatesfortune.com: AssociatesFortune.com Profiles Vivakor, Inc. & iMedicor

Vivakor, Inc. (OTCBB: VIVK); iMedicor (OTCBB: VMCI)

AssociatesFortune.com is part of Stock Profiler.US, LLC's News Division. Stock Profiler welcomes investors to sign up at www.stockprofiler.us. to subscribe to our FREE newsletter. Please follow our thread on www.twitter.com at StockProfilerUS

Stock Profiler is pleased to introduce Vivakor, Inc. (OTCBB: VIVK) to the investment community. Please visit us at www.stockprofiler.us for more detailed information.

-------------------------------------------

Vivakor, Inc. closed at $0.48 Wednesday, trading 12,500 shares.

Company News- October 8, 2009: Vivakor Launches Sales of VivaThermic Products to Exploding Biotech Sector in India

Vivakor, Inc. (OTCBB: VIVK) announced earlier today that distribution of its VivaThermic products to the rapidly growing biotech/biopharma industries in India through its agreement with Pro Lab Marketing Pvt. Ltd. This agreement gives Pro Lab Marketing distribution rights for Vivakor's VivaThermic cryovials in India. Pro Lab Marketing, based in New Delhi, is a well-established Indian supplier of biotechnology-related products and equipment throughout India.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About Vivakor, Inc.

Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. The R&D Core at Vivakor (the idea hub) innovates, develops and validates biomedical devices and biotechnologies. Commercialization of Vivakor technologies is accomplished through partnerships with manufacturers and niche-industry marketing and distribution leaders. Vivakor generates revenues through the licensing or sale of its technologies. Vivakor is preparing a portfolio of IP and subsidiaries. These will focus on the commercialization of technologies developed by Vivakor. More information can be found about Vivakor at www.vivakor.com.

-------------------------------------------

iMedicor closed at $0.089 Wednesday, trading 384,352 shares.

Company News- October 6, 2009: iMedicor Signs Agreement With Access Pharmaceuticals For the North American Commercial Launch of MUGARD(TM)

iMedicor (OTCBB: VMCI) announced Tuesday it has signed an agreement with Dallas-based Access Pharmaceuticals (OTCBB: ACCP) for the North American commercial launch of MuGard, its FDA-approved oral wound rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About iMedicor

iMedicor is the only HIPAA-compliant solution for interoperable health information transfer that is offered to physicians, healthcare providers and patients at no cost. The iMedicor portal enables disparate EMR (electronic medical record) systems to communicate, collaborate and exchange records in real time; pharmaceutical companies to deliver customized educational marketing programs to more than 730,000 healthcare providers nationwide in a highly targeted, cost-effective and non-intrusive manner. More information on iMedicor is available at www.imedicor.com.

-------------------------------------------

The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. AssociatesFortune.com is a division of Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.fastmoneytalk.com, www.markettelegraph.com, www.thewallstreetleader.com and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.

CONTACT: E-mail: info@stockprofiler.us Website: www.associatesfortune.com

Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes, Media Coverage, Google Finance, Google Analytics, Google, Yahoo Finance, Yahoo, MSNBC, Search Engine, AOL Finance, AOL, Market Wire, Businesswire, PR Newswire Alphatrade, Comtex, Comtex A, Comtex B, Zacks, Real Trader, Market News Publications, AFX U.K., Future World, JAGNotes.com, Internetwire, EURO PR News, First Call, PrimeZone, U.S. News, Forbes, Track Notes

CONTACT: AssociatesFortune.com e-mail: info@stockprofiler.us WWW: http://www.associatesfortune.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: acquisition, advisor, biomedical, biotechnology, broker, community, dealer, e-mail, euro, fda, finance, health, healthcare, india, investment, investment opinion, market, marketing, media, medicine, optics, pharmaceuticals, physicians, products, research, sales, securities, small cap, technology, track, web